Chemistry:Mecasermin
| Clinical data | |
|---|---|
| Trade names | Increlex |
| Other names | FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 5.8 hours[2] |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.71 g·mol−1 |
  (what is this?) (verify) | |
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[2][3][4]
Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[2]
A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[5] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[5]
References
- ↑ "Summary Basis of Decision (SBD) for Increlex". 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00524&lang=en.
- ↑ 2.0 2.1 2.2 2.3 "Increlex- mecasermin injection, solution". 7 May 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae.
- ↑ "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management 5 (3): 553–9. June 2009. doi:10.2147/tcrm.s6178. PMID 19707272.
- ↑ "Increlex". Drugs.com. https://www.drugs.com/increlex.html.
- ↑ 5.0 5.1 "IPLEXTM (mecasermin rinfabate [rDNA origin injection) Package Insert"]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021884s001lbl.pdf.
External links
- "Mecasermin". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/mecasermin.
 |  |
